Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. ATRC
stocks logo

ATRC

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
130.17M
+11.96%
-0.163
-4.31%
129.51M
+11.74%
-0.146
-14.14%
139.64M
+12.36%
-0.060
-24.5%
Estimates Revision
The market is revising Upward the revenue expectations for AtriCure, Inc. (ATRC) for FY2025, with the revenue forecasts being adjusted by 0.01% over the past three months. During the same period, the stock price has changed by -5.82%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-11.98%
In Past 3 Month
Stock Price
Go Down
down Image
-5.82%
In Past 3 Month
8 Analyst Rating
up Image0
Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 50.38 USD with a low forecast of 40.00 USD and a high forecast of 60.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 30.720
sliders
Low
40.00
Averages
50.38
High
60.00
up Image0
Current: 30.720
sliders
Low
40.00
Averages
50.38
High
60.00
Citizens Capital Markets
Daniel Stauder
Buy
Reiterates
$60
2025-04-02
Reason
Citizens Capital Markets
Daniel Stauder
Price Target
$60
2025-04-02
Reiterates
Buy
Reason
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$66 → $52
2025-03-28
Reason
Canaccord Genuity
William Plovanic
Price Target
$66 → $52
2025-03-28
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on AtriCure to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model folloing the company's Investor Day that both reiterated its 2025 guidance and provided an aspirational LRP that included three-year objectives as well as targets for 2030.
Needham
Mike Matson
Strong Buy
Reiterates
$51
2025-03-27
Reason
Needham
Mike Matson
Price Target
$51
2025-03-27
Reiterates
Strong Buy
Reason
JP Morgan
Lilia-Celine Lozada
Buy
Maintains
$51 → $46
2025-03-27
Reason
JP Morgan
Lilia-Celine Lozada
Price Target
$51 → $46
2025-03-27
Maintains
Buy
Reason
Needham
Mike Matson
Strong Buy
Reiterates
$51
2025-03-21
Reason
Needham
Mike Matson
Price Target
$51
2025-03-21
Reiterates
Strong Buy
Reason
Oppenheimer
Suraj Kalia
Buy
Maintains
$36 → $45
2025-02-13
Reason
Oppenheimer
Suraj Kalia
Price Target
$36 → $45
2025-02-13
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for AtriCure Inc (ATRC.O) is -62.37, compared to its 5-year average forward P/E of -49.77. For a more detailed relative valuation and DCF analysis to assess AtriCure Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-49.77
Current PE
-62.37
Overvalued PE
-37.32
Undervalued PE
-62.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
1170.79
Current EV/EBITDA
33.97
Overvalued EV/EBITDA
8464.57
Undervalued EV/EBITDA
-6122.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
6.30
Current PS
2.95
Overvalued PS
9.50
Undervalued PS
3.10

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areBuying! The buying amount has increased100%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

ATRC News & Events

Events Timeline

(ET)
2025-04-29
16:05:26
AtriCure sees FY25 revenue $517M-$527M, consensus $522.85M
select
2025-04-29
16:04:40
AtriCure reports Q1 adjusted EPS (14c), consensus (22c)
select
2025-03-26 (ET)
2025-03-26
13:10:05
AtriCure sees 2028 revenue $750M+, adjusted EBITDA margin 14%
select
Sign Up For More Events
Sign Up For More Events

News

Preview
8.0
06-30NASDAQ.COM
Interesting ATRC Put And Call Options For August 15th
  • Put Contract Analysis: The $30.00 put contract for ATRC stock offers a premium that lowers the effective purchase price to $29.95, presenting an attractive option for investors considering buying shares at a discount, with a 67% chance of expiring worthless.

  • Call Contract Strategy: The $35.00 call contract allows investors to sell shares at a profit if the stock price rises, providing a potential return of 7.71%, while also having a 55% chance of expiring worthless, allowing investors to retain both their shares and the premium collected.

Preview
4.0
04-30Benzinga
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
  • Analyst Rating Changes: Various Wall Street analysts have adjusted their price targets and ratings for several companies, including Visa (target raised), Starbucks (target lowered), and Airbnb (target lowered but rating upgraded to Buy).

  • Stock Performance Insights: The article provides current stock prices for the mentioned companies, highlighting significant changes in analyst outlooks that could influence investor decisions.

Preview
4.0
04-30Benzinga
Needham Maintains Buy on AtriCure, Lowers Price Target to $44
  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts and real-time intelligence for traders to enhance their market performance.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and accurate stock market insights.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is AtriCure Inc (ATRC) stock price today?

The current price of ATRC is 30.72 USD — it has decreased -4.18 % in the last trading day.

arrow icon

What is AtriCure Inc (ATRC)'s business?

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.

arrow icon

What is the price predicton of ATRC Stock?

Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 50.38 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is AtriCure Inc (ATRC)'s revenue for the last quarter?

AtriCure Inc revenue for the last quarter amounts to 123.62M USD, increased 13.57 % YoY.

arrow icon

What is AtriCure Inc (ATRC)'s earnings per share (EPS) for the last quarter?

AtriCure Inc. EPS for the last quarter amounts to -0.14 USD, decreased -50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for AtriCure Inc (ATRC)'s fundamentals?

The market is revising Upward the revenue expectations for AtriCure, Inc. (ATRC) for FY2025, with the revenue forecasts being adjusted by 0.01% over the past three months. During the same period, the stock price has changed by -5.82%.
arrow icon

How many employees does AtriCure Inc (ATRC). have?

AtriCure Inc (ATRC) has 1300 emplpoyees as of July 13 2025.

arrow icon

What is AtriCure Inc (ATRC) market cap?

Today ATRC has the market capitalization of 1.52B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free